News | Cardiovascular Surgery | August 08, 2016

ClearFlow Launches FDA-Cleared PleuraFlow System for Pediatric Cardiothoracic Surgery

Updated device features smaller tubes to prevent chest tube clogging after heart surgery

ClearFlow, PleuraFlow System, pediatric patients, cardiothoracic surgery

August 8, 2016 — ClearFlow Inc. announced in late July that its PleuraFlow Active Clearance Technology is now available for the treatment of pediatric cardiothoracic surgery patients. After receiving clearance from the U.S. Food & Drug Administration (FDA) earlier this year for expanded Indications for Use with the company’s patented technology, ClearFlow developed a new model of the PleuraFlow product for the pediatric market.

All patients undergoing heart surgery have some degree of bleeding, and thus, all patients require chest tubes to evacuate shed blood from around the heart and lungs in the early hours after surgery. The problem is that chest tubes often clog, which can limit the ability to evacuate shed blood. This can lead to complications including retained blood around the heart and lungs.

The composite of drainage-related complications that are detrimental to outcomes after cardiothoracic surgery and that may require early or late intervention to remediate is known as Retained Blood Syndrome (RBS). These clinical complications have significant economic consequences, including higher costs of care for patients, hospitals and society at large.

Inadequate drainage due to chest tube clogging is especially a problem for smaller diameter tubes required for pediatric heart surgery. When intensive care unit (ICU) care providers are concerned with chest tube clogging, they often resort to makeshift bedside techniques to strip or milk out clots, or break the sterile field and advance suction catheters or balloon catheters into the tube in an attempt to re-open them after they have clogged. These techniques are ineffective and potentially harmful.

The PleuraFlow System is a medical device that removes clots from chest tubes. A clogged chest tube can lead to retained blood around the heart and lungs. The new, smaller sized options are designed specifically for pediatric applications.

“We commonly hear from pediatric heart surgeons, pediatric intensive care specialists and ICU nurses that they encounter problems with chest tube clogging after heart surgery in children, and sometimes this results in preventable major complications or even fatal consequences. The older makeshift bedside techniques of stripping or milking conventional chest tubes has been shown ineffective to prevent these problems, and can even be harmful, and thus are banned in many hospitals,” said ClearFlow CEO Paul Molloy.

In a study published in the Annals of Thoracic Surgery, smaller 20 Fr chest tubes fitted with Active Clearance Technology cleared blood significantly better than larger 32 Fr chest tubes without active clearance technology. This was the first time it was demonstrated that smaller tubes can drain better than larger tubes if the lumen is preventatively kept clear of clot. The FDA recently cleared a 20 Fr System with four side holes, which is ideally suited for infant, preadolescent and adolescent patients undergoing congenital cardiac surgery. This system is also available in a 20 Fr with six side holes, as well as 24 Fr System when needed for larger pediatric patients.

For more information: www.clearflow.com

Related Content

Transplanting Pig Hearts Into Humans One Step Closer
News | Cardiovascular Surgery | December 11, 2018
The scientific journal Nature recently published an article from Munich University Hospital which describes the long-...
Bilateral Artery Use Does Not Improve 10-Year CABG Outcomes
News | Cardiovascular Surgery | September 06, 2018
While it is firmly established that the use of one internal thoracic artery can improve life expectancy in coronary...
Mandatory Public Coronary Artery Bypass Grafting Reporting Associated With Better Patient Outcomes
News | Cardiovascular Surgery | April 30, 2018
Mandatory public reporting of coronary artery bypass grafting (CABG) results in Massachusetts was associated with...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery | September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery | September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery | July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery | May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery | May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery | May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
Overlay Init